investor relations  icagen inc linkedin twitter why icagen blog investors about us leadership scientific team careers discovery services chemistry biology integrated drug discovery ion channels transporters tools  technologies biology in silico drug discovery compound logistics xrpro® technology resources publications brochures webinars posters news  events press releases in the news events contact us investor relations investors latest news icagen and omdana therapeutics announce collaboration to pursue therapies for patients with pulmonary hypertension jun  7 icagen to showcase its integrated drug discovery platform at bio international may  7 view all press releases upcoming event ion channel retreat 7 august   august  7 view all events sign up for email alerts be the first to receive breaking news sign up today company overview icagen is an integrated early discovery partner offering clients specialized technologies and deep scientific expertise to solve myriad challenges and optimize efficiency moving from target to lead the process begins with druggable targets and icagen scientists bring exceptional experience in kinases gpcrs ion channels and transporters icagen works with clients to determine drug feasibility using stateoftheart computational chemistry methods once a target is selected icagen can combine virtual screening ultrahigh throughput screening uhts biology and medicinal chemistry to generate viable leads in a much shorter time than has traditionally been possible officers  directors executive leadership board of directors timothy tyson chairman of the board tim tyson is chairman of icagen he has had  years of experience in the biopharmaceutical industry and with bristolmyers glaxo glaxo wellcome gsk valeant and aptuit he was on the executive committee at gsk where he was the… view full bio richard cunningham ceo and president richie cunningham is currently ceo of icagen inc he brings over  years of leadership experience in the healthcare and biopharmaceutical industry with premier inc valeant pharmaceuticals boehringer ingelheim and xrpro sciences inc… view full bio doug krafte phd chief scientific officer doug krafte is currently the chief scientific officer at icagen inc dr krafte has held a variety of positions over  years within the pharmabiotech sectors across multiple therapeutic areas most recently as executive director … view full bio mark korb chief financial officer mark korb has more than  years of experience with highgrowth companies taking startup operations to the next level prior to joining xrpro® he was group cfo and director of foodcorp a multimilliondollar consumer goods company… view full bio chris mathes chief commercial officer dr mathes joins icagen from charles river laboratories where he led north american business development efforts for discovery services richie cunningham ceo of icagen stated chris brings to icagen an expertise in sales marketing and… view full bio timothy tyson chairman of the board tim tyson is chairman of icagen he has had  years of experience in the biopharmaceutical industry and with bristolmyers glaxo glaxo wellcome gsk valeant and aptuit he was on the executive committee at gsk where he was the… view full bio benjamin warner phd founder xrpro sciences dr ben warner founded xrpro sciences in 0 following a stellar career as a scientist at the los alamos national laboratory in los alamos new mexico at los alamos he served as project leader for national security programs and garnered… view full bio edward roffman director mr roffman has been a director since december  since april 0 mr roffman has consulted either directly or through creekside llc with various early stage high technology companies during this time consulting projects have… view full bio clive kabatznik director mr kabatznik currently serves as the president of first south africa management a company that he founded that has been engaged in management consultancy services since january  from 0 until the present mr kabatznik has served… view full bio michael taglich director mr taglich is chairman of the board and president of taglich brothers inc a new york city based securities firm from  to  mr taglich served as a vice president at weatherly securities he brings a broad depth and breadth of… view full bio vincent palmieri director mr palmieri is a vice president of taglich brothers inc and specializes in sourcing evaluating and executing new investments as well as monitoring existing investments in small public and private companies mr palmieri received a… view full bio  7 icagen inc all rights reserved privacy policy disclaimer site map linkedin twitter pfizer to acquire icagen  business wire pfizer to acquire icagen july    am eastern daylight time new york ny and research triangle park ncbusiness wirepfizer inc nyse pfe and icagen inc nasdaq icgn today announced that they have entered into a definitive merger agreement pfizer which currently owns approximately  of icagen’s fully diluted shares will acquire the remaining  million shares at a price of  per share the aggregate transaction value including the value of the shares currently owned by pfizer is approximately  million in 07 pfizer and icagen entered into a worldwide collaboration for the discovery development and commercialization of compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders these sodium ion channels are important in the generation of electrical signals in nerve fibers that mediate the initiation transmission and sensation of pain by selectively targeting these sodium channels the companies are seeking to develop effective treatments for serious pain disorders with fewer side effects “we’re excited that icagen a global leader in pain research will join pfizer further strengthening our innovative core” said ruth mckernan senior vice president pfizer’s pain  sensory disorders and regenerative medicine unit known as neusentis “icagen’s capabilities and core ion channel technology will help to further expand pfizer’s position in the pain relief disease area and our ability to develop potential firstinindustry drugs for the treatment of pain and related disorders” we are delighted to announce today pfizer’s agreement to acquire icagen during the nearly four years since the initiation of our collaboration each side has developed a mutual appreciation of the expertise and capabilities of the other by joining forces in a more integrated manner we believe that our joint efforts towards the identification and development of novel pharmaceuticals targeting specific ion channels will be significantly enhanced noted p kay wagoner phd chief executive officer of icagen importantly i would like to take this opportunity to acknowledge the dedicated efforts of our employees who have been responsible for the progress we have made we very much look forward to continuing our efforts as a part of the pfizer research organization under the terms of the definitive merger agreement pfizer will promptly commence a tender offer to purchase all of the outstanding shares of icagen common stock for  per share in cash the agreement also provides for the parties to effect subject to customary conditions a merger to be completed following the completion of the tender offer which would result in all shares not tendered in the tender offer being converted into the right to receive  per share in cash the completion of the tender offer is conditioned on pfizer acquiring sufficient shares to own a majority of the shares of icagen on a fullydiluted basis and other customary conditions the companies are targeting closing before the end of the year jp morgan securities llc acted as financial advisor to icagen pfizer inc working together for a healthier world™ at pfizer we apply science and our global resources to improve health and wellbeing at every stage of life we strive to set the standard for quality safety and value in the discovery development and manufacturing of medicines for people and animals our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines as well as nutritional products and many of the world’s bestknown consumer products every day pfizer colleagues work across developed and emerging markets to advance wellness prevention treatments and cures that challenge the most feared diseases of our time consistent with our responsibility as the world’s leading biopharmaceutical company we also collaborate with health care providers governments and local communities to support and expand access to reliable affordable health care around the world for more than  years pfizer has worked to make a difference for all who rely on us to learn more about our commitments please visit us at wwwpfizercom more information is available at wwwpfizercom about icagen icagen inc is a biopharmaceutical company based in research triangle park north carolina focused on the discovery development and commercialization of novel orallyadministered small molecule drugs that modulate ion channel targets utilizing its proprietary knowhow and integrated scientific and drug development capabilities icagen has identified multiple drug candidates that modulate ion channels the company is conducting research and development activities in a number of disease areas including epilepsy pain and inflammation the company has two clinical stage programs in epilepsy and pain to learn more about icagen please visit our website at wwwicagencom disclosure notice this release contains forwardlooking statements related to pfizer icagen and the acquisition of icagen by pfizer that are not historical facts pfizer and icagen have identified some of these forwardlooking statements with words like believe may could would might possible will should expect intend plan anticipate or continue the negative of these words other terms of similar meaning or the use of future dates forwardlooking statements in this release include without limitation statements regarding the expected timing of the completion of the acquisition of icagen by pfizer and the potential benefits of the acquisition including the expected impact of the acquisition on pfizer’s position in and the potential of research and development in the pain relief disease area investors and security holders are cautioned not to place undue reliance on these forwardlooking statements actual results could differ materially from those currently anticipated due to a number of risks and uncertainties risks and uncertainties related to the acquisition of icagen by pfizer that could cause results to differ from expectations include uncertainties as to the timing of the transaction uncertainties as to how many of icagens shareholders will tender their shares in the offer the risk that competing offers will be made the possibility that various closing conditions for the transaction may not be satisfied or waived the effects of disruption from the transaction and the fact that the announcement of the transaction may make it more difficult to maintain relationships with employees and other business partners the risk of shareholder litigation in connection with the transaction and the related significant costs of defense indemnification and liability other business effects including the effects of industry economic political or regulatory conditions outside of pfizers and icagens control transaction costs actual or contingent liabilities pfizers ability to realize the expected benefits from its acquisition of icagen and other uncertainties related to the business of icagen and pfizer in addition the compounds described in this release are subject to all risks inherent in the drug development process and there can be no assurance that the development of these compounds will be commercially successful forwardlooking statements in this release should be evaluated together with other risks and uncertainties discussed in pfizers and icagens filings with the us securities and exchange commission the sec including the risk factors sections of pfizers and icagens most recent annual report on form k and subsequent quarterly reports on form q as well as the tender offer documents to be filed by eclipse acquisition corp a subsidiary of pfizer and the solicitationrecommendation statement to be filed by icagen neither pfizer nor icagen undertakes any obligation to update any forwardlooking statements as a result of new information future developments or otherwise except as expressly required by law all forwardlooking statements in this announcement are qualified in their entirety by this cautionary statement additional information the tender offer described in this release has not yet commenced and this release is not a recommendation an offer to purchase or a solicitation of an offer to sell shares of icagen’s stock at the time the tender offer is commenced pfizer will cause a new subsidiary eclipse acquisition corp to file a tender offer statement on schedule to and related exhibits with the sec investors and icagen shareholders are strongly advised to read the tender offer statement and related exhibits including the offer to purchase letter of transmittal and related tender offer documents and the related solicitationrecommendation statement on schedule d that will be filed by icagen with the sec because they will contain important information these documents will be available at no charge on the secs website at wwwsecgov in addition a copy of the offer to purchase letter of transmittal and certain other related tender offer documents once they become available may be obtained free of charge by directing a request to pfizer at wwwpfizercom a copy of the tender offer statement and the solicitationrecommendation statement will be made available to all shareholders of icagen free of charge at wwwicagencom contacts pfizerjoan campion media727suzanne harnett investors7icagenrichard d katz mdmedia and investors contacts pfizerjoan campion media727suzanne harnett investors7icagenrichard d katz mdmedia and investors search advanced news search advanced news search log in sign up richard cunningham  icagen inc linkedin twitter why icagen blog investors about us leadership scientific team careers discovery services chemistry biology integrated drug discovery ion channels transporters tools  technologies biology in silico drug discovery compound logistics xrpro® technology resources publications brochures webinars posters news  events press releases in the news events contact us richard cunningham investors richard cunningham ceo and president richie cunningham is currently ceo of icagen inc he brings over  years of leadership experience in the healthcare and biopharmaceutical industry with premier inc valeant pharmaceuticals boehringer ingelheim and xrpro sciences inc now icagen inc mr cunningham has experience and depth in a broad array of roles and responsibilities including mergers  acquisitions business development strategy development product launch contracting market access and sales  marketing his experience includes the commercialization and launch of multiple products in the infectious disease dermatology oncology cardiovascular respiratory and diabetes therapeutic areas mr cunningham joined icagen inc in late november of  and has since led the company through two transformational acquisitions from pfizer and sanofi in july  pfizer carolina site and july  sanofi arizona site he has led the company from a single technology in xrpro to a research team with leading expertise in the early drug discovery phase through these key strategic acquisitions mr cunningham has positioned icagen as an innovative integrated drug discovery company with unique expertise in the field of ion channel transporter neuroscience muscle biology and rare disease targets while also covering many other classes of drug discovery targets and therapeutic areas in addition to establishing his healthcare career richie also excelled as a professional athlete in the nfl holding allpro honors for the dallas cowboys green bay packers then later the carolina panthers and jacksonville jaguars his career in the nfl spanned from  until his retirement in 02  7 icagen inc all rights reserved privacy policy disclaimer site map linkedin twitter contact us  icagen inc linkedin twitter why icagen blog investors about us leadership scientific team careers discovery integrated drug discovery chemistry hit exploration multiparametric sar optimization hit to lead optimization ip assessment analytical chemistry compound storage  management biology highthroughput screening hts in vitro adme stem cells assay development ion channels transporters tools  technologies chemistry automated chemistry compound purification biology assay miniaturization molecular biology  biomarkers cell lines automated patch clamp high content screening xrpro® technology in silico drug discovery high performance computing hpc molecular dynamics chemoinformatics qsar  qspr modeling binding site analysis compound logistics resources publications brochures webinars posters news  events press releases in the news events contact us contact us we’d love to hear from you contact us wed love to hear from you please feel free to contact us directly using this form by phone or via email infoicagencom in japan  inquiries regarding icagens drug discovery services and products can be answered by contacting on target co ltdinfoontargetddsscojphttpwwwontargetddsscojp icagen corp hq emperor blvdsuite 0durham nc 2770 icagent inc0 e innovation park driveoro valley az 7  7 icagen inc all rights reserved privacy policy disclaimer site map linkedin twitter icagen inc linkedin twitter why icagen blog investors about us leadership scientific team careers discovery integrated drug discovery chemistry hit exploration multiparametric sar optimization hit to lead optimization ip assessment analytical chemistry compound storage  management biology highthroughput screening hts in vitro adme stem cells assay development ion channels transporters tools  technologies chemistry automated chemistry compound purification biology assay miniaturization molecular biology  biomarkers cell lines automated patch clamp high content screening xrpro® technology in silico drug discovery high performance computing hpc molecular dynamics chemoinformatics qsar  qspr modeling binding site analysis compound logistics resources publications brochures webinars posters news  events press releases in the news events contact us advancingearly drug discovery challenge discover solve lead explore icagen discovery chemistry exploration and optimization of chemical series to ensure fast progression and continual enhancement of our chemical estate of small molecules learn more discovery biology broad range of fully integrated drug discovery activities – from target identification to lead generation and beyond learn more ion channels  transporters marketleading experience in the characterization and development of optimized ion channel modulator drug candidates and transporters learn more spotlight well electrophysiology  accelerating ion channel characterization and new drug candidate identification  november   employing the syncropatch pe to characterize human disease associated ion… more information » latest press release icagen and omdana therapeutics announce collaboration to pursue therapies for patients with pulmonary hypertension june  7 view all press releases latest blog earlystage planning for endstage success june  7 view all blog articles icageninc transforming the pharmaceutical industry pipeline with in silico approaches drugdiscovery icagen httpstcotuujfxae • november 2   pm icageninc register for free ionchannels webinar sponsored by icageninc  it will be recorded so you can view it later httpstcoduwtctvil • october 2   pm investor relations resources  7 icagen inc all rights reserved privacy policy disclaimer site map linkedin twitter bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one icagen inc linkedin twitter why icagen blog investors about us leadership scientific team careers discovery integrated drug discovery chemistry hit exploration multiparametric sar optimization hit to lead optimization ip assessment analytical chemistry compound storage  management biology highthroughput screening hts in vitro adme stem cells assay development ion channels transporters tools  technologies chemistry automated chemistry compound purification biology assay miniaturization molecular biology  biomarkers cell lines automated patch clamp high content screening xrpro® technology in silico drug discovery high performance computing hpc molecular dynamics chemoinformatics qsar  qspr modeling binding site analysis compound logistics resources publications brochures webinars posters news  events press releases in the news events contact us advancingearly drug discovery challenge discover solve lead explore icagen discovery chemistry exploration and optimization of chemical series to ensure fast progression and continual enhancement of our chemical estate of small molecules learn more discovery biology broad range of fully integrated drug discovery activities – from target identification to lead generation and beyond learn more ion channels  transporters marketleading experience in the characterization and development of optimized ion channel modulator drug candidates and transporters learn more spotlight well electrophysiology  accelerating ion channel characterization and new drug candidate identification  november   employing the syncropatch pe to characterize human disease associated ion… more information » latest press release icagen and omdana therapeutics announce collaboration to pursue therapies for patients with pulmonary hypertension june  7 view all press releases latest blog earlystage planning for endstage success june  7 view all blog articles icageninc transforming the pharmaceutical industry pipeline with in silico approaches drugdiscovery icagen httpstcotuujfxae • november 2   pm icageninc register for free ionchannels webinar sponsored by icageninc  it will be recorded so you can view it later httpstcoduwtctvil • october 2   pm investor relations resources  7 icagen inc all rights reserved privacy policy disclaimer site map linkedin twitter bbb search database of businesses charities  news items for full functionality of this site it is necessary to enable javascript here are the instructions how to enable javascript in your web browser no results found   ask bbb to develop a report on this business by clicking here bbb search tips use bbbs search bar above to check out businesses and charities from our comprehensive database of bbb business profiles enter any of the following into the search box business or charity name website url phone number email address or select from the categories in the droplist to search by type of business or type of charity want to know more about our rating system find out more here  need more info  try the search faqs bbb business profile  icagen inc home    business directory    laboratories  research  development    icagen inc this business is not bbb accredited is this your business claim it now icagen inc submit a review icagen inc business information   icagen inc  years in business  emperor blvd ste 0 durham nc 27700 email website find a location bbb file opened 000 business started 20 business incorporated 20 in nc type of entity corporation contact information principal dr p kay wagoner president dr richard katz cfo business category laboratories  research  development products  services icagen inc offers commercial medical research services number of employees   see less business information see more business information business information a bbb rating scorecard share your experience submit a review submit a complaint bbb reason for ratings bbb rating is based on  factors get the details about the factors considered bbb reports on licensing licensing information is provided in the bbb business profiles to inform the public about industries that may require professional licensing bonding or registration better business bureau encourages you to check with the appropriate agency to be certain any requirements are currently being met advertising review bbb promotes truth in advertising by contacting advertisers whose claims conflict with the bbb code of advertising these claims come to our attention from our internal review of advertising consumer complaints and competitor challenges bbb asks advertisers to substantiate their claims change ads to make offers more clear to consumers and remove misleading or deceptive statements government actions bbb reports on known significant government actions involving the businesss marketplace conduct out of business bbb reports on a company that is out of business for three years from the date the company closes its doors or ceases to do business misuse of better business bureau namelogo bbb reports on unauthorized use of the better business bureaus name andor logo for as long as the business continues to use it in any advertising or for one year after the business ceases any repeated unauthorized uses bankruptcy bbb reports on a business’s bankruptcy as long as the business remains in bankruptcy mail returned bbb reports when mail sent to the business was returned by the postal service icagen inc bbb rating scorecard this business is not bbb accredited icagen inc a bbb rating system overview customer review rating the bbb customer review rating represents the customers opinion of the business the customer review rating percentages are based on the total number of positive neutral and negative reviews posted there are no reviews for this businessbe the first to leave a review this business has no complaints filed share your experience submit a review submit a complaint share print × claim your business by claiming your business profile businesses can add custom text or descriptive information about their services insert company logos and add photographs for consumers to view close × accreditedquestionmodal title content close × customer rating modal title content close × score modal title content close × find a location filter close icagen inc company profile  bloomberg feedback icagen inc public company company profile sector health care industry health care facilities  svcs subindustry health care services icagen inc provides a platform for drug discovery and development services to pharmaceutical and biotechnology companies the company offers scientific expertise and comprehensive access to technologies for ion channel and transporter drug discovery and development icagen also offers a broad range of cell lines and technologies for ion channel and transporter research corporate information address  emperor blvd suite 0 durham nc 2770 united states phone  fax  web url wwwicagencom board members chairman company timothy tyson avara pharmaceutical services inc cofounder company board members company michael taglich taglich brothers inc show more from the web key executives richard cunningham richie presidentceo mark j korb chief financial officer douglas krafte chief scientific officer sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data